Evidence in support of this possibility is provided by the finding in the larger COVID-19 study mentioned above [6] that patients with severe symptoms exhibit a sustained elevation of plasma IFN-α, whereas those with mild symptoms show a moderate decline. This evidence concerns the gene IFNA1 and COVID-19.